Georgia Bio Statement on BD Sterilization Plant In Georgia

Closure May Lead to Medical Device Shortage & Impact Patients

October 25, 2019 06:06 PM Eastern Daylight Time

ATLANTA–( BUSINESS WIRE )–Georgia Bio member companies are dedicated to improving patients’ lives-enhancing patient safety and expanding patient access to innovative treatments. Public health and environmental protection are central to the values of the life sciences community. Our member companies continually strive to exceed regulations and reduce their environmental footprint.

We are very concerned with the potential shut down of BD’s Covington facility over the use of EtO. Ethylene oxide is the safest, and sometimes, only method for ensuring the sterilization of medical devices for clinicians and patients. Approximately 50% of all medical devices are sterilized using EtO, accounting for more than 20 billion devices annually in the U.S. Many of our members manufacture devices and products that cannot be sterilized by any other means due to their complex nature, including pacemakers, implantable defibrillators, cardiac catheters, biopsy instruments and surgical fixation devices and vascular access devices including PICCs, midlines and ports. BD is the largest supplier of urinary catheters that are used in almost every surgical procedure that takes longer than 2 hours. They are also one of the only suppliers for pediatric vascular access devices used to deliver chemotherapy to children with cancer.

Georgia Bio believes policy makers have an obligation to protect the public from harmful emissions from any source, and we believe all industrial facilities in our state should meet or exceed safety standards. We support an open and transparent debate regarding EtO that is grounded in scientific fact, but caution that a hasty decision to close this facility or severely restrict the use of ethylene oxide would endanger the health of thousands, possibly even millions, of patients who are relying on sterile medical products.

About Georgia Bio

Georgia Bio is an independent, non-profit 501(c)(3) trade association whose mission is to advance the growth of Georgia’s life sciences industry and foster strategic partnerships that can create a healthier world. Georgia Bio member companies are dedicated to improving patients’ lives – enhancing patient safety and expanding patient access to innovative treatments. Public health and environmental protection are central to the values of the life sciences community. Georgia Bio members include bioscience and medtech companies, academic and research institutions, life science service providers, digital health companies, and related organizations. For more information, visit  www.gabio.org  or follow us on  Twitter @Georgia_Bio.

Contacts

Joseph Santoro 
404-334-7538 
jsantoro@gabio.org

March 17, 2026
Georgia Life Sciences leads effort to establish bipartisan caucus focused on advancing the state’s growing life sciences economy
March 13, 2026
A skilled workforce is the engine that will drive growth across America’s biotechnology industry, and Atlanta has built multi-faceted training programs that are developing and sustaining the talent pipeline for everything from advanced laboratory research to industrial biomanufacturing.
March 12, 2026
On March 12, 2026, Augusta, Georgia served as the setting for an important conversation about the future of American biotechnology and manufacturing. Manus welcomed members of the U.S. National Security Commission on Emerging Biotechnology (NSCEB) to its Augusta BioFacility to highlight how advanced biomanufacturing is strengthening U.S. supply chain resilience and supporting the growing bioeconomy. During the visit, Manus unveiled a significant expansion of its 44-acre Augusta BioFacility, increasing domestic capacity to produce critical biobased ingredients. The expansion further positions Georgia as a key hub for advanced biomanufacturing and demonstrates the growing role of biotechnology in strengthening national economic and supply chain security. Commission members met with leaders from industry, government, and academia to discuss strategies for scaling manufacturing infrastructure, strengthening resilient supply chains, and preparing the workforce needed to support the next generation of the U.S. bioeconomy. The visit also included conversations with Manus employees about the practical realities of building and operating advanced biomanufacturing facilities in the United States. The Augusta site has become one of the largest advanced biomanufacturing facilities in the country, producing a growing portfolio of bioalternatives at industrial scale. Among these products is high-purity Reb M, recently launched as Yume™ M Stevia Sweetener , supported by an all-Americas supply chain. “As we scale the Manus bioalternatives platform, Augusta has become a powerful example of what the modern U.S. bioeconomy looks like in practice,” said Manus Founder and CEO Ajikumar Parayil. The visit underscores Georgia’s expanding leadership in life sciences manufacturing and highlights how regional ecosystems can help advance U.S. leadership in biotechnology and biomanufacturing. Learn more about the expansion and visit: Manus welcomes U.S. National Security Commission on Emerging Biotechnology to unveil major Augusta BioFacility expansion Growing Georgia Biomanufacturing Industry Transforming American Industrial Strength
MORE POSTS